CURITY Pharma operates a vertically integrated cultivation and processing campus on a privately owned 67,000 m² site in the Industrial Park of Larissa.
Our cultivation, manufacturing and distribution operations are structured around GACP, EU-GMP and GDP requirements. Together, these quality systems provide end-to-end control of product safety, consistency, traceability and pharmaceutical quality.
Controlled cultivation
GACP: Quality begins in cultivation
Cannabis is a botanical product whose chemical composition can vary according to genetics and cultivation conditions. GACP-controlled processes help minimise this variability and establish reproducible pharmaceutical starting material before it enters manufacturing.
- Genetic identity and cultivar consistency
- Controlled cultivation conditions
- Contamination prevention
- Standardised harvesting and drying
- Seed-to-harvest traceability
- Reliable cannabinoid and terpene profiles
Pharmaceutical manufacturing
EU-GMP: Transforming botanical material into medicine
EU-GMP governs pharmaceutical manufacturing and ensures that every batch is produced and controlled according to predefined quality standards.
For medical cannabis products, this provides assurance of identity, purity, potency, microbiological quality and stability throughout the manufacturing lifecycle.
- Qualified facilities and equipment
- Validated manufacturing processes
- Environmental monitoring
- Quality-control laboratories
- Batch testing and stability studies
- Electronic traceability
- Qualified personnel
- CAPA and continuous improvement
Controlled distribution
GDP: Maintaining quality after manufacturing
Medical cannabis products must remain protected throughout storage and transportation. GDP controls preserve product quality until medicines reach pharmacies, hospitals and patients.
- Controlled storage conditions
- Continuous temperature monitoring
- Secure transportation
- Counterfeit prevention
- Distribution traceability
- Qualified wholesalers
- Documented recall capability